Institutional members access full text with Ovid®

Share this article on:

Concomitant Use of Panobinostat and Reirradiation in Progressive DIPG: Report of 2 Cases.

Wang, Zhihong J. MD, PhD; Ge, Yubin PhD; Altinok, Deniz MD; Poulik, Janet MD; Sood, Sandeep MD; Taub, Jeffrey W. MD; Edwards, Holly BS; Kieran, Mark W. MD, PhD; Steven, Miller MD
Journal of Pediatric Hematology/Oncology: Post Author Corrections: February 23, 2017
doi: 10.1097/MPH.0000000000000806
Clinical and Laboratory Observations: PDF Only

Diffuse intrinsic pontine glioma (DIPG) remains a devastating disease. Panobinostat has been shown to have therapeutic efficacy both in vitro and in DIPG orthotopic xenograft models; however, clinical data in patients with DIPG are lacking. We present 2 cases of DIPG, who were treated with panobinostat at 22 to 25 mg/m2/dose, 3 times weekly for 2 weeks in 3-week cycles and concomitant reirradiation after disease progression. Two episodes of asymptomatic thrombocytopenia were observed in 1 patient. Hyperacetylation of histone H4 of peripheral blood mononuclear cells was evident following treatment. In our experience, panobinostat administered with reirradiation was well tolerated at a relatively higher dose than that used in adult studies.

Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.